首页/数据集/Genomic profiling of immature hematopoietic cells to obtain insights into imatinib resistance

Genomic profiling of immature hematopoietic cells to obtain insights into imatinib resistance

ChEBI2024-01-01 更新2026-07-12 收录

血液肿瘤基因组学

药物耐药机制

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-MTAB-11899 数据链接链接失效反馈

官方服务：

资源简介：

Genomic profiling of immature hematopoietic cells to obtain insights into imatinib resistance

应用场景：

创建时间：

2024-01-01

血液肿瘤基因组学

骨髓纤维化

FFPE Bone marrow core biopsis of a cohort of 16 APMF Samples were analysed by OncoScan copy number analysis (E-MTAB-7888). 5 out of this 16 Samples had enough DNA available for NGS using the Illumina

NIAID Data Ecosystem90

Genetic study of non-Langerhans cell histiocytosis

血液肿瘤基因组学

MAPK信号通路突变

The clinical features and prognosis of non-Langerhans cell histiocytosis (non-LCH) remained poorly defined. Although recurrent somatic activating mutations of BRAFV600E and additional genetic drivers

NIAID Data Ecosystem80

Additional file 5: of PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

多发性骨髓瘤靶向治疗

药物耐药机制

Table S4. EZH2i target genes are mostly bivalent in XG7 HMCLs (XLSX 10Â kb)

NIAID Data Ecosystem50

SAM Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

肿瘤靶向治疗

药物耐药机制

Protein arginine methyltransferase 5 (PRMT5) over-expression in hematological and solid tumors methylates arginine residues on cellular proteins involved in important cancer functions including cell c

NIAID Data Ecosystem90

RUNX1 mutations in lower-risk MDS. Homo sapiens

血液肿瘤基因组学

骨髓增生异常综合征进展

Study of effect of RUNX1 mutations on lower-risk MDS patients

NIAID Data Ecosystem60